Principal Financial Group Inc Edgewise Therapeutics, Inc. Transaction History

Principal Financial Group Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 29, 2024	SELL	$15.08 - $21.23 $55,509 - $78,147	-3,681 Reduced 21.96%	13,084 $235,000
Q1 2024 Apr 29, 2024	BUY	$9.25 - $19.97 $3,376 - $7,289	365 Added 2.23%	16,765 $305,000
Q4 2023 Feb 07, 2024	SELL	$5.51 - $12.1 $6,397 - $14,048	-1,161 Reduced 6.61%	16,400 $179,000
Q3 2023 Nov 02, 2023	BUY	$5.73 - $7.69 $8,474 - $11,373	1,479 Added 9.2%	17,561 $100,000
Q2 2023 Aug 07, 2023	BUY	$5.71 - $10.29 $22,291 - $40,172	3,904 Added 32.06%	16,082 $124,000
Q1 2023 May 09, 2023	BUY	$6.66 - $11.33 $8,191 - $13,935	1,230 Added 11.23%	12,178 $81,000
Q4 2022 Feb 09, 2023	BUY	$7.58 - $11.08 $82,985 - $121,303	10,948 New	10,948 $97,000

191

100M

2.17M

410K

Ticker EWTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 63,171,700
Market Cap $1.94B
Description
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has c...

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

Stay updated on Principal Financial Group Inc with notifications on news.